New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:49 EDTADXSAdvaxis to conduct 4 cancer immunotherapy clinical trials with GRU Cancer Center
Advaxis announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The four clinical trials will be designed to assess: High dose, repeating cycles of ADXS-HPV in recurrent or refractory cervical cancer. ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. The optimal combination dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer. ADXS-HPV prior to surgery in patients with surgically treatable cervical cancer.
News For ADXS From The Last 14 Days
Check below for free stories on ADXS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2014
07:36 EDTADXSAdvaxis issued notice of allowance of two patents in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use